Hong Kong · Delayed Price · Currency is HKD Xuanzhu Biopharmaceutical Statistics
Total Valuation
HKG:2575 has a market cap or net worth of HKD 17.38 billion. The enterprise value is 16.66 billion.
| Market Cap | 17.38B |
| Enterprise Value | 16.66B |
Important Dates
The last earnings date was Monday, March 30, 2026.
| Earnings Date | Mar 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HKG:2575 has 517.95 million shares outstanding. The number of shares has increased by 3.15% in one year.
| Current Share Class | 160.70M |
| Shares Outstanding | 517.95M |
| Shares Change (YoY) | +3.15% |
| Shares Change (QoQ) | +6.30% |
| Owned by Insiders (%) | 1.82% |
| Owned by Institutions (%) | 5.93% |
| Float | 74.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 301.71 |
| PB Ratio | 11.40 |
| P/TBV Ratio | 15.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -60.97 |
| EV / Sales | 289.13 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.75, with a Debt / Equity ratio of 0.00.
| Current Ratio | 3.75 |
| Quick Ratio | 3.01 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,757.30 |
Financial Efficiency
Return on equity (ROE) is -21.10% and return on invested capital (ROIC) is -11.69%.
| Return on Equity (ROE) | -21.10% |
| Return on Assets (ROA) | -9.60% |
| Return on Invested Capital (ROIC) | -11.69% |
| Return on Capital Employed (ROCE) | -15.36% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 292,449 |
| Profits Per Employee | -1.39M |
| Employee Count | 197 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 0.26 |
Taxes
In the past 12 months, HKG:2575 has paid 6,677 in taxes.
| Income Tax | 6,677 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 50.09 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 35.37 |
| Average Volume (20 Days) | 2,237,487 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HKG:2575 had revenue of HKD 57.61 million and -273.20 million in losses. Loss per share was -0.59.
| Revenue | 57.61M |
| Gross Profit | 37.13M |
| Operating Income | -242.49M |
| Pretax Income | -273.20M |
| Net Income | -273.20M |
| EBITDA | -211.85M |
| EBIT | -242.49M |
| Loss Per Share | -0.59 |
Balance Sheet
The company has 725.81 million in cash and 719,988 in debt, with a net cash position of 725.09 million or 1.40 per share.
| Cash & Cash Equivalents | 725.81M |
| Total Debt | 719,988 |
| Net Cash | 725.09M |
| Net Cash Per Share | 1.40 |
| Equity (Book Value) | 1.52B |
| Book Value Per Share | 2.94 |
| Working Capital | 679.51M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 31.65M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 64.45% |
| Operating Margin | -420.89% |
| Pretax Margin | -474.20% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HKG:2575 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.15% |
| Shareholder Yield | -3.15% |
| Earnings Yield | -1.57% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |